Is Jisandai (Bingtonsha) a free national drug?

Epclusa is an oral drug against hepatitis C virus developed by Gilead of the United States. It is a compound drug composed of two active ingredients, sofosbuvir (Sofosbuvir) and velpatasvir (Velpatasvir). It is suitable for the treatment of chronic hepatitis C virus (HCV) infection of all genotypes. Jisandai (Bingtonsha) has remarkable therapeutic effects and is widely used around the world. It is an important breakthrough in the treatment of hepatitis C.

However, Jisandai (Bingtonsha) is not a free drug in the country. Although the Chinese government is actively promoting the prevention and control of hepatitis C, Jisandai (Bingtonsa) is currently not included in the National Essential Drugs List or other large-scale free drug projects. If patients want to use Jisanda (Bingtonsa), they usually need to purchase it at their own expense or reimburse part of the cost through commercial medical insurance. China's basic medical insurance may cover part of the cost of Jisandai (Bingtonsha), but the specific reimbursement ratio and conditions vary by region.

It is worth noting that the state still provides certain support for the treatment of hepatitis C patients. In recent years, China has increased its efforts to screen for hepatitis C and launched hepatitis C treatment programs for special groups in some areas. These programs may provide free screening and some treatment support, but not all antiviral drugs.

In order to reduce the financial burden on patients, Gilead and some non-governmental organizations have also launched drug assistance projects in some areas, providing G3 (Bintongsha) at a discounted price, or giving some patients the opportunity to take the drug for free under special circumstances. However, these aids are not equivalent to a free drug policy at the national level. The application conditions are stricter and the coverage is limited.

In general,Jisandai (Bingtonsha) Although it is not a free drug in the country, its status in the treatment of hepatitis C cannot be ignored. If patients need to use Jisandai (Bingtonsha), they should first consult a doctor to learn about the treatment plan that suits them. At the same time, you can pay attention to local policies, insurance reimbursement and pharmaceutical assistance programs to minimize financial pressure.